Substances Containing AuCs and Preparation Method and Use Thereof

Abstract

Disclosed are a pharmaceutical use of a gold cluster and a substance containing the gold cluster and the preparation method and use thereof. The gold cluster and substance containing the gold cluster can inhibit the aggregation of Aβ and α-syn, has excellent effects on the levels of cell models and animal models, and can be used to prepare drugs for preventing and treating Alzheimer's disease and/or Parkinson's disease.

What is claimed is: 
     
         1 . A method for treating a subject with Parkinson's disease, said method comprising:
 administrating a pharmaceutical composition into the subject with Parkinson's disease in an effective amount;   wherein said pharmaceutical composition comprising a substance containing gold clusters (AuCs); wherein said substance comprises:
 AuCs; and 
 a ligand Y coating the AuCs externally, wherein the ligand Y is a thiol-containing compound; 
   wherein the AuCs have a gold core diameter smaller than 3 nm;   wherein the thiol-containing compound is one selected from the group consisting of:   L-cysteine, D-cysteine, N-acetyl-L-cysteine (L-NAC), N-acetyl-D-cysteine (D-NAC), L-cysteine-L-arginine dipeptide (CR), L-arginine-L-cysteine dipeptide (RC), L-histidine-L-cysteine dipeptide (HC), L-cysteine-L-histidine dipeptide (CH), glycine-L-cysteine-L-arginine tripeptide (GCR), L-proline-L-cysteine-L-arginine tripeptide (PCR), L-lysine-L-cysteine-L-proline tripeptide (KCP), L-glutathione (GSH), glycine-L-serine-L-cysteine-L-arginine tetrapeptide (GSCR), glycine-L-cysteine-L-serine-L-arginine tetrapeptide (GC SR), 1-[(2S)-2-methyl-β-thiol-1-oxopropyl]-L-proline, thioglycollic acid, mercaptoethanol, thiophenol, D-β-trolovol, N-(2-mercaptopropionyl)-glycine, and dodecyl mercaptan.   
     
     
         2 . The method of  claim 1 , wherein the AuCs have a gold core diameter in the range of 0.5-2.6 nm. 
     
     
         3 . Use of a substance containing gold clusters (AuCs) for manufacture of a medicament for the treatment of Parkinson's disease in a subject, wherein said substance comprises:
 AuCs; and   a ligand Y coating the AuCs externally, wherein the ligand Y is a thiol-containing compound;   wherein the AuCs have a gold core diameter smaller than 3 nm;   wherein the thiol-containing compound is one selected from the group consisting of:   L-cysteine, D-cysteine, N-acetyl-L-cysteine (L-NAC), N-acetyl-D-cysteine (D-NAC), L-cysteine-L-arginine dipeptide (CR), L-arginine-L-cysteine dipeptide (RC), L-histidine-L-cysteine dipeptide (HC), L-cysteine-L-histidine dipeptide (CH), glycine-L-cysteine-L-arginine tripeptide (GCR), L-proline-L-cysteine-L-arginine tripeptide (PCR), L-lysine-L-cysteine-L-proline tripeptide (KCP), L-glutathione (GSH), glycine-L-serine-L-cysteine-L-arginine tetrapeptide (GSCR), glycine-L-cysteine-L-serine-L-arginine tetrapeptide (GC SR), 1-[(2S)-2-methyl-β-thiol-1-oxopropyl]-L-proline, thioglycollic acid, mercaptoethanol, thiophenol, D-β-trolovol, N-(2-mercaptopropionyl)-glycine, and dodecyl mercaptan.   
     
     
         4 . The use of  claim 3 , wherein the AuCs have a gold core diameter in the range of 0.5-2.6 nm.